Meropenem and Pseudo-bartter syndrome - a phase IV clinical study of FDA data

Summary:

Pseudo-bartter syndrome is reported as a side effect among people who take Meropenem (meropenem), especially for people who are male, 50-59 old, also take Coly-Mycin M, and have Acinetobacter infection.

The phase IV clinical study analyzes which people have Pseudo-bartter syndrome when taking Meropenem. It is created by eHealthMe based on reports of 33,250 people who have side effects when taking Meropenem from the FDA, and is updated regularly.

What is Meropenem?

Meropenem has active ingredients of meropenem. eHealthMe is studying from 33,295 Meropenem users. Check the latest studies of Meropenem.

What is Pseudo-bartter syndrome?

Pseudo-bartter syndrome (diuretic abuse) is found to be associated with 10 drugs and 68 conditions by eHealthMe. Check the latest studies of Pseudo-bartter syndrome.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

33,250 people reported to have side effects when taking Meropenem.
Among them, 12 people (0.04%) have Pseudo-bartter syndrome.

Could Meropenem cause Pseudo-bartter syndrome?

Among these 12 people:

What is the gender of people who have Pseudo-bartter syndrome when taking Meropenem? *

female: 33.33 %
male: 66.67 %

What is the age of people who have Pseudo-bartter syndrome when taking Meropenem? *

What are other drugs people take besides Meropenem? *

What are other side effects people have besides Pseudo-bartter syndrome? *

Metabolic Alkalosis (too much bicarbonate in the blood): 3 people, 25.00%
Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 3 people, 25.00%
Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood): 3 people, 25.00%
Hypokalemia (low potassium): 3 people, 25.00%
Hypocalcaemia (levels of calcium in blood serum are abnormally low): 3 people, 25.00%
Hypercalciuria (elevated calcium (ca+) level in the urine): 3 people, 25.00%
Staphylococcus Test Positive: 1 person, 8.33%

What are the existing conditions these people have? *

Acinetobacter Infection (infection by group of bacteria commonly found in soil and water): 4 people, 33.33%
Septic Shock (shock due to blood infection): 3 people, 25.00%
Wound Infection Pseudomonas: 1 person, 8.33%
Urosepsis (secondary infection that occurs when a urinary tract infection spreads to the bloodstream): 1 person, 8.33%
Skin Ulcer: 1 person, 8.33%
Respiratory Distress (difficulty in breathing): 1 person, 8.33%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 1 person, 8.33%
Pneumonia: 1 person, 8.33%
Pain: 1 person, 8.33%
Lung Infiltration (a substance that normally includes fluid, inflammatory exudates or cells that fill a region of lung): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Meropenem and have Pseudo-bartter syndrome?

- Check whether Pseudo-bartter syndrome is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Meropenem:

Meropenem (33,295 reports)

Browse all side effects of Meropenem:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pseudo-bartter syndrome:

Pseudo-bartter syndrome (10 drugs)

Browse all the conditions that are associated with Pseudo-bartter syndrome:

Pseudo-bartter syndrome (68 conditions)

Related publications that referenced our studies

Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .
Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on meropenem (the active ingredients of Meropenem) and Meropenem (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.